



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

<http://doi.org/10.5281/zenodo.3708954>
Available online at: <http://www.iajps.com>

Research Article

SUITABILITY OF INTRAVENOUS MAGNESIUM SULPHATE IN SEVERE ASTHMA BASED ON ITS ENDPOINT

¹Dr. Yousaf Raza, ²Dr. Saima Hassan, ³Dr. Muhammad Hasnain¹BVH Bahawalpur²THQ Kallur Kot Bhakhar³THQ Hospital Kallur Kot

Article Received: January 2020

Accepted: February 2020

Published: March 2020

Abstract:

Objective: Continued enthusiasm for intravenous magnesium sulfate to use it in many different signs other than controlling eclamptic attacks has led analysts to try it as the smooth muscle relaxant in patients of severe bronchial asthma. The outcomes were mostly debatable, subsequently researchers led the current investigation to decide the suitability of intravenous magnesium sulphate in severe asthma founded on its endpoint.

Methods: Our current research was conducted at BVH Bahawalpur from October 2018 to September 2019. We thoughtfully checked all cases of severe asthma conceded during the review period on the treatment charts and extracted important data. Each of the patients was first treated with standard asthma therapy and then given 4ml of 53% (2g) MgSO₄ weakened MgSO₄ in 260ml of typical saline solution intravenously. The results were displayed in rate and frequency while the calm age was displayed as \pm SD on average.

Results: The average age of people was 46.30 ± 21.2 years. Authors had the woman power in the sample population (62.4%). Patients who were effectively relieved were 34.4% while those who were no longer active were 58.6%. There was no significant gender distinction in result ($p > 0.06$).

Conclusion: Researchers originate that intravenous magnesium sulfate was ineffective in counselling cases through severe asthma with respect to improving endurance levels.

Keywords: Magnesium sulphate; Bronchial asthma; Effectiveness; Emergency administration.

Corresponding author:

Dr Yousaf Raza,
BVH Bahawalpur

QR code



Please cite this article in press Yousaf Raza et al., *Suitability Of Intravenous Magnesium Sulphate In Severe Asthma Based On Its Endpoint*, Indo Am. J. P. Sci, 2020; 07(03).

INTRODUCTION:

Asthma is the relentless illness of lower airways described through varying respiratory indications and airway obstructions. Their medical appearances are intermittent and frequently include shortness of breath, puffed, tightness and tightness in the chest. For hundreds of years, asthma has been common in 5-6% of the population and nearly 28% of cases needing confirmation [1]. This is surprisingly widespread by up to 2:12 grown-ups globally. Despite a very broad treatment methodology, standard asthma administration incorporates β_2 -agonists, inhaled anticholinergics, short-acting bronchodilators and corticosteroids. For cases inert to those underlying treatments, magnesium sulfate (MgSO_4) may be a therapeutic alternative [2]. In addition, it has been prescribed as an adjunct in the treatment of severe asthma with other mainline medications. In cases who do not reply to early medications and these through extreme, dangerous and intense intensities, the current rules call for the use of MgSO_4 as an adjunctive therapy to reduce clinical urgency and to improve the suction capacities, while the proof of the use of nebulized magnesium is still uncertain [3]. Intravenous MgSO_4 has high safety profile through regularly reported minor reactions including dry mouth, hot flashes, anxiety and death at ambition site. Possible drug interactions include potassium-sparing diuretics and glucagon, which, once applied concomitantly, rise serum magnesium levels. If it is not possible to use the two clusters of drugs at the same time, check for commonly reported problems or store the last drug incidentally, if possible [4]. Contraindications to use of MgSO_4 include myasthenia gravis, myocardial conditions, AV square and renal deception (creatinine clearance below 33 mL/min). There has been no survey from Pakistan on this topic in addition here is rare and conflicting information available on this subject, especially in Asia. Subsequently, the current review led to research on suitability of intravenous magnesium sulphate in severe asthma grounded on their findings [5].

METHODOLOGY:

Our current research was conducted at BVH Bahawalpur from October 2018 to September 2019. We thoughtfully checked all cases of severe asthma conceded during the review period on the treatment charts and extracted important data. Each of the patients was first treated with standard asthma therapy and then given 4ml of 53% (2g) MgSO_4

weakened MgSO_4 in 260ml of typical saline solution intravenously. The results were displayed in rate and frequency while the calm age was displayed as \pm SD on average. We have banned harmful cases, post-injury cases, post-injury cases, and patients on respiratory assistance from review. Viable factors were age and outcome (outdated, relieved, and hinted). However, we did not obtain data on the status of patients after referral. These patients were referred to emergency clinics with better treatment offices, at the request of their families or because of their attending physician's packages. Emergency Unit. Prior to this confirmation, most of the patients had a marked history of asthma and were receiving treatment with upkeep or potentially home-recovery medications. In adding, cases were receiving standard therapy (including nebulized salbutamol and ipratropium bromide, and deliberate hydrocortisone) for worsening asthma prior to receiving intravenous magnesium sulphate therapy. Each case was first treated with standard asthma therapy and then, for example, intravenous magnesium sulfate was administered with 5 mL of 53% (2 g) MgSO_4 weakened in 260 mL of regular saline and administered gradually over 25 minutes as suggested. Each of cases, after being stabilized, was transferred to the Department of Medicine.

Measurable examination: Information remained noted and stored on Microsoft Excel 2007 spreadsheets. Pertinent data was retrieved and reviewed on the SPSS 23 form. Sex and results remained displayed in rates in addition incidences, whereas age was entered as mean \pm SD. Chi-square testing was used to compare results across sexual orientations. The level of centrality remained established at $p < 0.06$.

RESULTS:

The overall 146 cases were included in survey throughout examination. The prevalence among women was 84 (62.4%) compared to 56 (41.8%) among men. The mean age was 46.28 ± 21.2 years. Patients who were restored were 34.5%, while those who were discontinued were 58.5%. Table 1 shows the statistical factors while Chart 1 shows the results according to the sexual orientation of the patients. There was no noticeable contrast between sexual orientations for the outcome; the fixation rate for males was 27(19.37%) versus 21(15.85%) ($p > 0.06$). A total of 79 (58.5%) patients lost their jobs regardless of MgSO_4 use.

Table 1: Demographic variables and results:

Variables	Data
Age (years)	46.28 ± 21.2
Female	83 (60.4)
Man	53 (39.7)
Cured	14 (10.3%)
Expired	44 (32.3%)
Referred	78 (57.4%)

DISCUSSION:

MgSO₄ has been used as a supplement in the monitoring of severe asthma, but there is still no satisfactory evidence of its viability. The vast majority of reviews have been conducted in the West and there is a large research gap in Asia-Pacific region. The work of MgSO₄ in asthma is still hazy, yet some reviews have clarified its method of activity [6]. The potential impacts of MgSO₄ on smooth muscle may comprise sodium-calcium siphons and obstruction of section and arrival of calcium from the endoplasmic reticulum, thus leading to a decrease in intracellular calcium. In addition, MgSO₄ suppresses acetylcholine discharge and discourages the overflow of muscle fibers into the nerve endings of the cholinergic motor, ultimately resulting in the unwinding of bronchial smooth muscle [7]. In addition, the collaboration between calcium and myosin is suppressed by magnesium sulfate which occurs in the unfolding of the muscle cell. Magnesium also reduces inflammatory intermediates by suppressing the degranulation of polar cells and balancing T cells. This might also enhance attractiveness of β_2 -agonist receptors afterwards by increasing their bronchodilator effect. In conclusion, it could legitimately reduce the severity of asthma by reinvigorating the prostacyclin/nitric oxide amalgam [8]. Additionally, the Cochrane review has detailed the viability of MgSO₄ in the treatment of severe asthma, although the ongoing review by Mohammed et al. found that the viability of MgSO₄ was only peripheral to aspiration work (MDS=0.26, 96% CI=0.02-0.52). In addition, it was not clear from the last survey whether MgSO₄ was adequate in adults. Nevertheless, it has been recommended that intravenous MgSO₄ appears to be actual in children [9]. This indicates that the results and decisions regarding the adequacy of magnesium sulfate in the acute asthma picture are mixed. We attempted another procedure to find out the viability of magnesium sulfate compared to previous reviews; these were routinely randomized measured trials, yet researchers applied a results-based review survey, inferring that magnesium sulfate was insufficient in executive asthma [10].

CONCLUSION:

Researchers found that intravenous magnesium sulfate is insufficient in the monitoring of cases through severe asthma. Nevertheless, more extensive investigations, mainly randomized screening and future investigations, are still needed to make unequivocal inferences around character of magnesium sulfate in administration of asthma.

REFERENCES:

1. Del Castillo J, Engbaek L. The nature of the neuromuscular block produced by magnesium. *The Journal of physiology*. 1954;124(2):370-84. [PubMed] [Free full text]
2. Bois P. Effect of magnesium deficiency on mast cells and urinary histamine in rats. *British journal of experimental pathology*. 1963;44(2):151-5. [PubMed] [Free full text]
3. Classen H, Jacob R, Schimatschek H. Interactions of Magnesium with Direct and Indirect Acting Sympathomimetic Amines. *Magnes Bull*. 1987;9(2):80- 7.
4. Aggarwal P, Sharad S, Handa R, Dwiwedi S, Irshad M. Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study.
5. Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. *Arch Pediatr Adolesc Med*. 2000;154(10):979–83. doi: 10.1001/archpedi.154.10.979. [PubMed] [Free full text]
6. Green SM, Rothrock SG. Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. *Ann Emerg Med*. 1992 Mar;21(3):260- 5. [PubMed]
7. Bittar TMB, Guerra SD. Use of intravenous magnesium sulfate for the treatment of severe acute asthma in children in emergency department. *Revista Brasileira de terapia intensiva*. 2012;24(1):86-90. [Free full text]
8. Kumar SA, Shailendranath G, Raj K. A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. *Iranian Journal of Allergy, Asthma and Immunology*. 2008;7(4):221-9. [Free full text]

9. Annesi-Maesano I. Epidemiology of asthma in the world and in France. *Rev Prat.* 2011 Mar;61(3):329-35. [PubMed]
10. Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J, et al. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. *Respiratory Medicine.* 2013;107(3):321-30. doi: 10.1016/j.rmed.2012.12.001.[PubMed] [Free full text]